On 19 June 2020, the National Department of Health released a statement titled, Follow up statement on Dexamethasone by the Minister of Health. The statement summarised the outcomes of the Randomised Evaluation of COVID-19 therapy (RECOVER) Trial, which reported benefit from the use of Dexamethasone in the patients with severe COVID-19. Based on the available results of the RECOVERY Trial, Dexamethasone is recommended in COVID-19 patients who require respiratory support only (i.e. those requiring ventilation or other forms of oxygen therapy). In the RECOVERY Trial, prednisone 40mg daily was used in women who were pregnant or breastfeeding.